Gilead Sciences held its 2026 annual meeting of stockholders on April 30, resulting in the election of nine directors and the ratification of Ernst & Young LLP as the company's independent auditor. Shareholders also approved executive compensation and the amended 2022 Equity Incentive Plan, but rejected several stockholder proposals regarding board leadership and ESG/DEI reporting.
